16th Jul 2012 15:14
Annual Information Update 2012
BTG plc (LSE:BTG) ("the Company") is pleased to provide its annual information update, in accordance with the requirements of the Prospectus Rule 5.2. This update refers to information that has been published or made available by the Company to the public over the twelve months ending today. To avoid an unnecessarily lengthy document, information is referred to in this update rather than included in full.
The information referred to in this update was up to date at the time the information was published but some information may now be out-of-date.
(1) Announcements made via RNS, a Regulatory Information Service
All of the documents listed below were published via RNS, a Regulatory Information Service on or around the dates indicated.
Date of publication | Brief Description of announcement |
6 July 2012 |
Total voting rights and share capital |
19 June 2012 | Notification of submission of documents to the National Storage Mechanism |
12 June 2012 | Applications submitted to FDA and EMA for approval of Lemtrada™ (alemtuzumab) for Multiple Sclerosis |
11 June 2012 | Director Notification under Listing Rule 9.6.14 |
8 June 2012 | Directors' Interests in shares of BTG plc |
31 May 2012 | Total voting rights and share capital |
29 May 2012 | Change of TIDM from BGC to BTG |
24 May 2012 | Total voting rights and share capital |
22 May 2012 | Notification of major interest in BTG plc shares |
21 May 2012 | Directors' Interests in shares of BTG plc |
21 May 2012 | Final Results announcement |
30 April 2012 | Total voting rights and share capital |
23 April 2012 | BTG announces positive results from second US Pivotal Phase III trial of Varisolve® |
12 April 2012 | Total voting rights and share capital |
4 April 2012 | Close Period Update |
2 April 2012 | Block Listing Return |
29 March 2012 | Director Notification under Listing Rule 9.6.14 |
8 March 2012 | ZYTIGA® (abiraterone acetate) second Phase III trial unblinded |
29 February 2012 | Additional listing of shares |
14 February 2012 | Directorate amendment |
31 January 2012 | Total voting rights and share capital |
30 January 2012 | BTG announces positive data from first US Phase III trial of Varisolve® |
26 January 2012 | Total voting rights and share capital |
25 January 2012 | Interim Management Statement |
23 January 2012 | Notification of major interest in BTG plc shares |
18 January 2012 | Voraxaze® (glucarpidase) receives US regulatory approval |
17 January 2012 | Director Notification under Listing Rule 9.6.14 |
6 January 2012 | Total voting rights and share capital |
3 January 2012 | Total voting rights and share capital |
7 December 2011 | Total voting rights and share capital |
7 December 2011 | Voraxaze® (glucarpidase) licensed to Ohara Pharmaceuticals in Japan |
30 November 2011 | Total voting rights and share capital |
30 November 2011 | Notification of major interest in BTG plc shares |
21 November 2011 | Total voting rights and share capital |
17 November 2011 | Half Yearly Report |
16 November 2011 | Total voting rights and share capital |
11 November 2011 | Directorate change |
8 November 2011 | Total voting rights and share capital |
4 November 2011 | Total voting rights and share capital |
1 November 2011 | Directorate change |
31 October 2011 | Total voting rights and share capital |
19 October 2011 | Additional listing of shares |
12 October 2011 | Notification of major interest in BTG plc shares |
5 October 2011 | Total voting rights and share capital |
5 October 2011 | Block Listing Return |
5 October 2011 | Pre close Update |
3 October 2011 | Total voting rights and share capital |
30 September 2011 | Total voting rights and share capital |
28 September 2011 | Notification of major interest in BTG plc shares |
20 September 2011 | FDA accepts BLA for Voraxaze® with priority review |
19 September 2011 | Total voting rights and share capital |
12 September 2011 | Total voting rights and share capital |
7 September 2011 | ZYTIGA® approved in the EU |
6 September 2011 | Total voting rights and share capital |
2 September 2011 | Total voting rights and share capital |
1 September 2011 | Directors' Interests in shares of BTG plc |
5 August 2011 | Notification of major interest in BTG plc shares |
3 August 2011 | Notification of major interest in BTG plc shares |
1 August 2011 | Notification of major interest in BTG plc shares |
29 July 2011 | Total voting rights and share capital |
26 July 2011 | Total voting rights and share capital |
25 July 2011 | Directors' Interests in shares of BTG plc |
20 July 2011 | Results of 2011 AGM |
20 July 2011 | AGM and Interim Management Statement |
14 July 2011 | Annual Information Update 2011 |
Copies of the above announcements can be downloaded from the Company's website (www.btgplc.com) or obtained from the Company Secretary at the Company's Registered Office, 5 Fleet Place, London, EC4M 7RD
(2) Documents filed at Companies House
All of the documents listed below were filed with Companies House in Cardiff on or around the dates indicated.
Date of filing | Brief Description of document |
7 June 2012 | Form SH01 Statement of Capital |
9 May 2012 | Form SH01 Statement of Capital |
2 February 2012 | Form SH01 Statement of Capital |
4 January 2012 | Form AP01 Appointment of Garry Watts as Director |
3 January 2012 | Form TM01 Resignation of John Brown as Director |
23 December 2011 | Form AR01 Annual Return |
6 December 2011 | Form SH01 Statement of Capital |
1 November 2011 | Form SH01 Statement of Capital |
29 September 2011 | Forms SH01 Statement of Capital |
27 July 2011 | Filing of special resolutions passed at AGM |
27 July 2011 | Form SH01 Statement of Capital |
18 July 2011 | Group Accounts made up to 31 March 2011 |
Copies of documents filed at Companies House can be obtained from Companies House or obtained from the Company Secretary at the Company's Registered Office. 5 Fleet Place, London EC4M 7RD
CONTACT: Andy Burrows
Director of Investor Relations
Telephone: 020 7575 1741
Related Shares:
BTG